Polydex Pharmaceuticals (OTCMKTS:POLXF) and JSR Corp/ADR (OTCMKTS:JSCPY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.
This is a summary of recent recommendations for Polydex Pharmaceuticals and JSR Corp/ADR, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings & Valuation
This table compares Polydex Pharmaceuticals and JSR Corp/ADR’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Polydex Pharmaceuticals||$5.28 million||0.52||$450,000.00||N/A||N/A|
|JSR Corp/ADR||$3.81 billion||0.93||$272.18 million||$1.34||11.64|
JSR Corp/ADR has higher revenue and earnings than Polydex Pharmaceuticals.
JSR Corp/ADR pays an annual dividend of $0.17 per share and has a dividend yield of 1.1%. Polydex Pharmaceuticals does not pay a dividend. JSR Corp/ADR pays out 12.7% of its earnings in the form of a dividend.
Insider & Institutional Ownership
0.0% of JSR Corp/ADR shares are held by institutional investors. 12.9% of Polydex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Polydex Pharmaceuticals and JSR Corp/ADR’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Polydex Pharmaceuticals has a beta of -0.36, meaning that its stock price is 136% less volatile than the S&P 500. Comparatively, JSR Corp/ADR has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500.
JSR Corp/ADR beats Polydex Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
About Polydex Pharmaceuticals
Polydex Pharmaceuticals Limited, through its subsidiaries, manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It also develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market. The company primarily offers dextran and derivative products, including Iron Dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. It also provides ferric hydroxide and hydrogenated dextran to Sparhawk Laboratories Inc. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product for the treatment of cystic fibrosis, a genetic disease. Polydex Pharmaceuticals Limited sells its iron dextran primarily to independent distributors and wholesalers primarily in Europe, the Far East, South America, and Canada; and Dextran Sulphate to independent distributors or companies in the United States and Europe for analytical applications. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was founded in 1966 and is based in Toronto, Canada.
About JSR Corp/ADR
JSR Corporation provides petrochemical products, and fine chemicals and other products in Japan and internationally. The company operates through three segments: Elastomers Business, Plastics Business, and Fine Chemicals and Other Products Business. The Elastomers Business segment offers general purpose synthetic rubbers, including emulsion polymerization styrene-butadiene (SB), solution polymerization SB, styrene, polybutadiene, and isoprene rubbers; special-purpose synthetic rubbers, such as nitrile, butyl, ethylene propylene, and NV and NE polymer blend rubbers; and thermoplastic elastomers comprising syndiotactic 1,2-polybutadiene, hydrogenated polymers, SB thermoplastic elastomers, styrene-isoprene thermoplastic elastomers, TPE compound products, etc. It also provides emulsion products consisting of paper coating latex, SB latex, acrylic emulsions, asphalt pavement modifiers, etc.; and performance chemicals, including high-functional dispersants, organic/inorganic hybrid coating materials, battery materials, and thermal management materials. The Plastics Business segment offers styrenic resins, such as acrylonitrile-butadiene-styrene plastic and acrylonitrile-ethylene-propylene-styrene plastic products. The Fine Chemicals and Other Products Business segment provides semiconductor materials comprising lithography materials, chemical mechanical planarization materials, and packaging materials; display materials consisting of liquid crystal display and flat panel display materials; and optical materials, including precision and processing business materials. It also offers life sciences materials, such as in-vitro diagnostic and research reagents, and bioprocess materials; and lithium ion capacitors. JSR Corporation has collaboration with Aspect Biosystems to develop human liver tissue. The company was formerly known as Japan Synthetic Rubber Co., Ltd. JSR Corporation was founded in 1957 and is headquartered in Tokyo, Japan.
Receive News & Ratings for Polydex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polydex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.